logo-loader
viewInhibikase Therapeutics, Inc.

Inhibikase Therapeutics receives clinical clearance from FDA on its Parkinson's disease therapy

Inhibikase Therapeutics Inc President & CEO Milton Werner sat down with Proactive Investors at the ThinkEquity Conference in New York. The Atlanta-based, privately-held pharma company is focused on developing and commercializing small-molecule kinase inhibitor therapeutics for the treatment of neurological infections and neurodegenerative diseases.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Primary Health Properties 'in robust shape' and playing its part in fight...

Primary Health Properties PLC's  (LON:PHP) Harry Hyman and Richard Howell tell Proactive London's Andrew Scott they're working with health authorities to utilise its properties better during the current coronavirus crisis. They add that all of its rents are effectively guaranteed by the...

6 hours, 37 minutes ago

2 min read